

NEW DRUGS

中国药学会系列期刊/《CAJ-CD》规范执行优秀期刊/美国《化学文摘》荷兰SCOPUS等国际著名检索系统收录
中国中文核心期刊 中国科技核心期刊 中国科学引文数据库来源期刊

中国新药杂志

二〇一九年

第二十八卷

第二十期

第2433-2552页

半月刊

CHINESE JOURNAL OF NEW DRUGS

ISSN 1003-3734
CN 11-2850/R
CODEN ZXZHA6

中国新药杂志



20
2019
Vol.28 | No.20

- 蛋白酶体的两面性和药物设计
- 我国生物医药产业园区发展现状及存在问题
- 2019年第一季度我国医药工业经济运行情况分析
- 口服固体制剂一致性评价质量研究和体外评价的常见问题分析
- 卵巢癌靶向抑制剂的研究进展
- 中药固体制剂溶出行为研究进展

www.newdrug.cn

ISSN 1003-3734



国家药品监督管理局主管



万方数据

目次

半月刊 1992年创刊
第28卷第20期 2019年10月30日出版

•新药述评与论坛•

- 2433 蛋白酶体的两面性和药物设计.....郭宗儒
2440 我国生物医药产业园区发展现状及存在问题.....徐凯, 孙利华
2447 我国高发肿瘤的NCCN及CSCO治疗指南用药特征研究.....张松林, 艾丹丹, 张冉, 等
2453 基于PubMed数据库的非霍奇金淋巴瘤治疗现状和研究热点聚类分析.....张亚妮, 武芬, 王书敏, 等
2461 2019年第一季度我国医药工业经济运行情况分析.....郭文, 钟一鸣, 周斌

•新药注册与审评技术•

- 2468 浅谈化学药物强制降解试验的设计与开展.....郭涤亮
2473 口服固体制剂一致性评价质量研究和体外评价的常见问题分析.....石靖, 许真玉

•重大新药创制专项巡礼•

- 2478 GC-MS法测定缬沙坦中的*N*-亚硝基二甲胺.....吴兆伟, 杜凯, 王琳, 等

•生物医药前沿•

- 2482 重组蛋白质制品注射液渗透压摩尔浓度值测定的能力验证.....秦玺, 丁有学, 张河战, 等

•综述•

- 2486 卡博替尼治疗恶性肿瘤的临床研究进展.....汪龙, 张莉, 汪娟, 等
2492 卵巢癌靶向抑制剂的研究进展.....王智文, 唐海飞, 郑雪松, 等
2498 中药固体制剂溶出行为研究进展.....张婧, 黎翩, 孙阳恩, 等
2502 新型头孢菌素头孢比罗酯特点及临床应用.....阮亘杰, 刘美琼, 马雅坤, 等

•药物临床试验核查专栏•

- 2508 从药物临床试验数据核查看研究者的职责履行情况.....高荣, 吕术超, 李秀丽, 等
2513 从药物临床试验数据核查看伦理委员会的职责履行情况.....高荣, 唐静, 方翔, 等
2518 从药物临床试验数据核查看药物临床试验机构的职责履行情况.....高荣, 宁靖, 王安娜, 等

•药物临床试验质量管理与提升专栏•

- 2524 我国新药临床试验受试者教育工作的现状和推进策略.....李树婷, 郝鹏, 毛冬蕾, 等
2529 研究者发起的临床研究中知情同意书签署情况现状分析.....李会娟, 宋玫, 王美容, 等

•临床研究•

- 2533 帕利哌酮联合社会认知训练对认知功能的影响.....李轶琛, 马筠, 谢俊, 等

•实验研究•

- 2537 川陈皮素对高糖诱导的大鼠肾小球系膜细胞炎症因子和氧化应激水平的影响.....李会英, 赵晓丽, 王丽, 等
2543 光纤法在线考察盐酸曲美他嗪缓释片释放度.....聂微, 雷方, 李健华, 等
2548 不同产地黄芩花中的5种有害元素测定及其无机元素的主成分分析和聚类分析.....李宝霞, 董双涛, 马邦

[期刊基本参数] CN11-2850/R*1992*sm*A4*120*zh*P*¥50.00**22*2019-10

责任编辑 赵文锐 英文审校 魏尔清 杜小莉 张鲸惊

2433	Dual characters of proteasomes and drug design	GUO Zong-ru
2440	Development status and problems of biomedical industrial parks in China	XU Kai, SUN Li-hua
2447	Study on drug characteristics of NCCN and CSCO clinical practice guidelines for high-prevalence tumors in China	ZHANG Song-lin, AI Dan-dan, ZHANG Ran, <i>et al</i>
2453	Cluster analysis of the current status and research hotspots of non-Hodgkin's lymphoma based on PubMed database	ZHANG Ya-ni, WU Fen, WANG Shu-min, <i>et al</i>
2461	Economic operation of Chinese pharmaceutical industry in the first quarter of 2019	GUO Wen, ZHONG Yi-ming, ZHOU Bin
2468	Considerations on the design and implementation of chemical drugs stress testing	GUO Di-liang
2473	Common problems analyses in the quality control and <i>in vitro</i> evaluation on consistency evaluation of oral solid dosage forms	SHI Jing, XU Zhen-yu
2478	Determination of the contents of <i>N</i> -nitrosodimethylamine in valsartan by GC-MS	WU Zhao-wei, DU Kai, WANG Lin, <i>et al</i>
2482	The proficiency testing for determination of osmolality of recombinant protein injection	QIN Xi, DING You-xue, ZHANG He-zhan, <i>et al</i>
2486	Progress in clinical research on cabozantinib in the treatment of malignant tumors	WANG Long, ZHANG Li, WANG Juan, <i>et al</i>
2492	Advances in the targeted inhibitors of ovarian cancer	WANG Zhi-wen, TANG Hai-fei, ZHENG Xue-song, <i>et al</i>
2498	Research progress on dissolution behavior of solid preparations of traditional Chinese medicine	ZHANG Qiang, LI Pian, SUN Yang-en, <i>et al</i>
2502	Review of the features and clinical application of a novel broad-spectrum cephalosporin: ceftobiprole medocartil	RUAN Gen-jie, LIU Mei-qiong, MA Ya-kun, <i>et al</i>
2508	Perspectives on the performing of investigators' responsibilities from drug clinical trial data inspection	GAO Rong, L Shu-chao, LI Xiu-li, <i>et al</i>
2513	Perspectives on the implementation of ethics committee's responsibilities from drug clinical trial data inspection	GAO Rong, TANG Jing, FANG Xiang, <i>et al</i>
2518	Perspectives on the implementation of responsibilities of drug clinical trial institutions from drug clinical trial data inspection	GAO Rong, NING Jing, WANG An-na, <i>et al</i>
2524	The status and promotion strategy of subjects education in clinical trials of new drugs in China	LI Shu-ting, HAO Peng, MAO Dong-lei, <i>et al</i>
2529	Analysis of problems related to informed consent in investigator-initiated clinical researches	LI Hui-juan, SONG Mei, WANG Mei-rong, <i>et al</i>
2533	Effect of paliperidone combined with social cognitive training on cognitive function	LI Yi-chen, MA Jun, XIE Jun, <i>et al</i>
2537	Effects of nobiletin on high glucose-induced inflammatory cytokines and oxidative stress in rat mesangial cells	LI Hui-ying, ZHAO Xiao-li, WANG Li, <i>et al</i>
2543	Online monitoring the dissolution of trimetazidine dihydrochloride sustained-release tablets with fiber-optic dissolution test system	NIE Wei, LEI Fang, LI Jian-hua, <i>et al</i>
2548	Determination of five hazardous elements in <i>Wikstroemia</i> from different areas and principal component analysis and cluster analysis of inorganic elements	LI Bao-xia, DONG Shuang-tao, MA Zheng

Directed by: National Medical Products Administration
Sponsored by: China Medical Science Press
China National Pharmaceutical Group Corp.
Chinese Pharmaceutical Association
Editor-in-Chief: SANG Guo-wei
Board Chairman: SHI Sheng-yi
Edited by: Editorial Board of Chinese Journal of New Drugs
Published by: Chinese Journal of New Drugs Co., Ltd.
Address: Room 317, No.3 Chengming Building, No.2 Xizhimen South Street, Xicheng District, Beijing 100035, China
Tel: (010)52722697 / 52722651 / 52723707

Website: <http://www.newdrug.cn>
E-mail: bianjibu@newdrug.cn
Printer: Beijing Kexin Printing Co., Ltd.
Domestic Distribution: Beijing Post Offices
Overseas Distribution: China International Book Trading Corp.
(P.O.Box 399 Beijing, China)
Domestic Subscription: Local Post Offices
Periodical Registration: ISSN 1003-3734 CN 11-2850/R
Publication Date: October 30, 2019
Copyright: 2019 by Chinese Journal of New Drugs Co., Ltd.